Takeda's Entyvio approved in Europe for UC and Crohn's
One week after receiving a double win with US regulators, Takeda has secured approval in Europe for Entyvio (vedolizumab) in both its ulcerative colitis and Crohn's disease indications.
One week after receiving a double win with US regulators, Takeda has secured approval in Europe for Entyvio (vedolizumab) in both its ulcerative colitis and Crohn's disease indications.